QHSLab (USAQ)
OTHER OTC:USAQ
Top Page
QHSLab
(OTC:USAQ)
Select Model
Select Model
Rating:57Neutral
Price Target:
$0.72
▲(46.33% Upside)
Action:UpgradedDate:01/27/26
The score is held back primarily by weak financial quality (negative equity and ongoing net losses) and limited valuation support (negative P/E). Offsetting factors include strong technical momentum (price above key moving averages with positive MACD) and positive corporate developments around debt reduction and growth/product initiatives.
Positive Factors
Major debt reduction and deleveraging
Substantial retirement of legacy convertible debt materially lowers fixed interest burden and dilution risk, improving free cash flow and financial flexibility. This structural deleveraging supports sustained investment in product development, sales scaling, and credible governance improvements over the medium term.
Negative Factors
Negative stockholders’ equity
Persistently negative equity is a structural capital weakness that constrains financing options and exposes shareholders to dilution or solvency risk. It reduces capacity to absorb shocks, complicates lending or uplisting efforts, and makes future growth more dependent on external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Major debt reduction and deleveraging
Substantial retirement of legacy convertible debt materially lowers fixed interest burden and dilution risk, improving free cash flow and financial flexibility. This structural deleveraging supports sustained investment in product development, sales scaling, and credible governance improvements over the medium term.
Read all positive factors
QHSLab (USAQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.43M
Dividend YieldN/A
Average Volume (3M)6.57K
Price to Earnings (P/E)16.0
Beta (1Y)0.93
Revenue Growth43.55%
EPS Growth-461.90%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding11,281,527
10 Day Avg. Volume9,209
30 Day Avg. Volume6,568
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)-4.20
Price to Sales (P/S)1.20
P/FCF Ratio17.91
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue2.86
Enterprise Value/Gross Profit4.31
Enterprise Value/Ebitda26.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)N/A
QHSLab Business Overview & Revenue Model
Company Description
QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support...
How the Company Makes Money
USA Equities makes money primarily through the sale of its medical devices and digital healthcare solutions. The company's revenue streams include direct sales to healthcare providers and institutions, licensing agreements for its proprietary tech...
QHSLab Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
25
Negative
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.61M | 2.13M | 1.41M | 1.24M | 1.41M | 124.53K |
| Gross Profit | 1.73M | 1.36M | 793.61K | 619.52K | 670.75K | 50.09K |
| EBITDA | 278.24K | 352.39K | -91.29K | -434.60K | -487.63K | -296.40K |
| Net Income | -386.75K | -259.24K | -468.36K | -996.00K | -770.18K | -327.39K |
Balance Sheet | ||||||
| Total Assets | 1.73M | 1.80M | 1.68M | 1.96M | 2.21M | 297.86K |
| Cash, Cash Equivalents and Short-Term Investments | 158.39K | 157.17K | 51.58K | 178.69K | 286.86K | 94.34K |
| Total Debt | 1.21M | 1.72M | 1.78M | 1.68M | 1.30M | 631.00K |
| Total Liabilities | 2.35M | 2.41M | 2.06M | 1.88M | 1.38M | 906.19K |
| Stockholders Equity | -610.91K | -607.76K | -375.62K | 76.25K | 824.07K | -608.33K |
Cash Flow | ||||||
| Free Cash Flow | 135.13K | 142.44K | -159.63K | -388.11K | -509.31K | -197.26K |
| Operating Cash Flow | 135.13K | 142.44K | -159.63K | -350.99K | -354.74K | -165.56K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -37.12K | -154.57K | -31.70K |
| Financing Cash Flow | -72.69K | -36.85K | 32.52K | 279.95K | 701.82K | 268.02K |
QHSLab Technical Analysis
Neutral
0.49
Price Trends
0.70
Negative
0.54
Positive
0.37
Positive
Market Momentum
-0.01
Positive
38.28
Neutral
23.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USAQ, the sentiment is Neutral. The current price of 0.49 is below the 20-day moving average (MA) of 0.66, below the 50-day MA of 0.70, and above the 200-day MA of 0.37, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 38.28 is Neutral, neither overbought nor oversold. The STOCH value of 23.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for USAQ.
QHSLab Risk Analysis
QHSLab disclosed 45 risk factors in its most recent earnings report. QHSLab reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
QHSLab Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $6.43M | 16.04 | ― | ― | 43.55% | -461.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $2.83M | -0.28 | -191.39% | ― | ― | 76.53% | |
42 Neutral | $1.82M | -3.70 | -173.74% | ― | 82.96% | 82.04% | |
41 Neutral | $2.43M | -0.69 | -6046.59% | ― | -8.93% | 97.80% | |
41 Neutral | $627.27K | -0.05 | -2268.26% | ― | -12.39% | 44.61% |
* Healthcare Sector Average
USAQ
QHSLab
0.57
0.32
128.00%
NUWE
Nuwellis
1.05
-38.43
-97.34%
AEMD
Aethlon Medical
2.15
-26.49
-92.49%
VERO
Venus Concept
0.34
-2.45
-87.92%
VTAK
Catheter Precision
1.09
-5.45
-83.33%
BBLG
Bone Biologics
1.11
-3.69
-76.88%
QHSLab Corporate Events
Business Operations and StrategyFinancial Disclosures
QHSLab Reports 2025 Preliminary Results and Debt Reduction
Positive
Jan 26, 2026
On January 26, 2026, QHSLab reported preliminary unaudited financial results for 2025 showing revenue rose just over 25% to $2.68 million and gross profit increased more than 32% to $1.80 million, with gross margins improving from about 64% to rou...
Business Operations and StrategyPrivate Placements and Financing
QHSLab Simplifies Capital Structure With Debt-for-Equity Deal
Positive
Jan 23, 2026
QHSLab, Inc. entered into a Note Repurchase Agreement with MedScience Research Group, Inc. under which it repurchased, cancelled, and extinguished a promissory note originally issued on June 23, 2021, that had an outstanding principal and accrued ...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesPrivate Placements and Financing
QHSLab Expands Board to Strengthen Governance and Uplisting Plans
Positive
Jan 16, 2026
On January 16, 2026, QHSLab announced that it has begun a formal process to expand its board of directors by adding independent members, aiming to strengthen corporate governance, enhance oversight, and support future capital markets objectives, i...
Business Operations and StrategyFinancial Disclosures
QHSLab Reports Strong 2025 Growth and Deleveraged Balance Sheet
Positive
Jan 6, 2026
On January 6, 2026, QHSLab issued an unaudited financial and operational update ahead of an investor session, reporting that revenue for the nine months ended September 30, 2025 rose 32% year over year to $1.99 million, with gross profit of $1.32 ...
Business Operations and StrategyPrivate Placements and Financing
QHSLab Modifies Debt and Converts Note to Equity
Neutral
Jan 2, 2026
On December 31, 2025, QHSLab, Inc. entered into a Promissory Note Modification and Partial Conversion Agreement with creditor Alex Mirakian MD PA, under which $126,548 of a previously issued convertible note’s principal and accrued interest ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
QHSLab strengthens balance sheet with new equity financing
Positive
Dec 29, 2025
On December 26, 2025, QHSLab raised approximately $500,000 in a private placement of common stock and warrants to two accredited investors, issuing about 1.67 million shares at $0.30 per share and 416,666 warrants exercisable at $0.60 through 2030...
Business Operations and StrategyProduct-Related Announcements
QHSLab Launches Q-Cog™ for Early Dementia Detection
Positive
Dec 3, 2025
On December 3, 2025, QHSLab announced the launch of Q-Cog™, a cloud-based cognitive assessment tool designed to aid primary care providers in the early detection of Mild Cognitive Impairment and dementia. The tool combines cognitive, behavio...
Business Operations and StrategyRegulatory Filings and Compliance
QHSLab Releases December 2025 Corporate Presentation
Neutral
Dec 1, 2025
QHSLab, Inc. released its December 2025 Corporate Presentation on December 1, 2025, detailing its business and operations. The presentation, furnished under Regulation FD, emphasizes the company’s commitment to transparency and the use of va...
Business Operations and StrategyFinancial Disclosures
QHSLab Reports Strong Revenue Growth and Debt Reduction
Positive
Nov 24, 2025
QHSLab, Inc. reported a transformational year in 2025, marked by significant revenue growth and a strengthened balance sheet, as highlighted in their recent shareholder letter. The company achieved $1.99 million in revenue for the first nine month...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
QHSLab Retires Convertible Debt, Strengthens Financial Position
Positive
Nov 18, 2025
On November 18, 2025, QHSLab, Inc. completed a Note Repurchase Agreement to retire over $1.4 million in defaulted convertible debt, originally issued in 2021 and 2022, for a cash payment of $300,000. This strategic move strengthens QHSLab’s ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.